TrialInflammatory bowel diseases2024

Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.

Geert D'Haens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.